Briacell Therapeutics Corp (BCTX)

$7.05 -0.69 (-8.91%)
Market Cap 14.58M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 120,800
Avg Vol 68,224
Day's Range N/A - N/A
Shares Out 1.88M
Stochastic %K 16%
Beta 1.38
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
WallStreetBuyDip
WallStreetBuyDip Dec. 30 at 3:11 AM
Comparing trending tickers $BCTX vs $RARE: BCTX has dropped to $7.05, showing an 8.91% decrease, with trading volume reaching 120.7K, slightly above its average of 104.8K. On the other hand, RARE has taken a sharper hit, declining 42.32% to $19.72, on a significantly higher volume of 21.7M shares, which is well over 15 times its usual volume of 1.4M. While both stocks are experiencing higher than average trading activity, RARE's dramatic price drop and massive volume surge indicate a more volatile market response compared to BCTX.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 30 at 2:56 AM
Comparing trending tickers $PPLT vs $BCTX: PPLT dropped significantly to $192.78, a 12.43% decrease, on a high trading volume of 3.2M shares, which is well above its average (about 8 times the norm). BCTX also saw a decline, down 8.91% to $7.05, with trading volume reaching 120.7K shares, slightly above its usual volume. While both stocks experienced notable drops, PPLT's trading activity was particularly high compared to its average, suggesting a more dramatic shift in investor sentiment.
0 · Reply
MoeMaze
MoeMaze Dec. 30 at 12:27 AM
$BCTX $BCTX Plenty of trials, plenty of promises — somehow the stock was the only casualty. #bctx #briacell @BriaCell #stocks #cancer #nasdaq
0 · Reply
MoeMaze
MoeMaze Dec. 30 at 12:26 AM
$BCTX $BCTX Less than 4 months I said it , and here.. it’s happening again ! New public offering, which made the #stock go down by 30%Mr Willy “ William” and then what ! … Do u enjoy “ #SUCKING #MONEY “ that much !plz enough and try to find something other than money! 😉
0 · Reply
MoeMaze
MoeMaze Dec. 30 at 12:17 AM
$BCTX #Public offering ➡️ Reverse split,Public offering ➡️ Reverse split,Public offering 🔂.. till when R we gonna stay in this vicious Circle? and all under the excuse of “ New #Cancer treatment “ , I think u R the real Cancer, and WE need to find a treatment! $BCTX @BriaCell #Stocks
1 · Reply
JohnTrack
JohnTrack Dec. 29 at 11:44 PM
$BCTX eyes peeled, nothing forced...
0 · Reply
JohnTrack
JohnTrack Dec. 29 at 9:11 PM
$BCTX financial results released https://www.rapidticker.com/news/bctx-sec-filing-0c70d2
0 · Reply
MarkeTimer
MarkeTimer Dec. 29 at 8:34 PM
$BCTX 25mm shares at $3?
1 · Reply
JediGreen
JediGreen Dec. 29 at 6:39 PM
$BCTX You guys want to see how Bullish I am. This is how much money I’m paying on Taxes just to keep my position in this stock.
1 · Reply
GoldenChic
GoldenChic Dec. 29 at 4:35 PM
$BCTX keep feeding the daytrader...
1 · Reply
Latest News on BCTX
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 11 days ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 19 days ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 20 days ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 27 days ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 4 weeks ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 5 weeks ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 5 weeks ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 7 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 7 weeks ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 22, 2025, 7:30 AM EDT - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 2 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 2 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 2 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 3 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 4 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 4 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 4 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 5 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 5 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 15, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 6 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 10, 2025, 7:30 AM EDT - 6 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 9, 2025, 7:30 AM EDT - 6 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 8, 2025, 7:30 AM EDT - 6 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jul 2, 2025, 7:30 AM EDT - 6 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 24, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 4, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Jun 2, 2025, 7:30 AM EDT - 7 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 27, 2025, 7:30 AM EDT - 7 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 23, 2025, 7:30 AM EDT - 7 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

BriaCell CEO Letter to Shareholders

May 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell CEO Letter to Shareholders

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 30, 2025, 7:30 AM EDT - 8 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 28, 2025, 7:30 AM EDT - 8 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 8:00 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 10:11 AM EDT - 8 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 24, 2025, 7:30 AM EDT - 8 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 23, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 22, 2025, 7:30 AM EDT - 8 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Apr 16, 2025, 7:30 AM EDT - 9 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 26, 2025, 8:00 AM EDT - 9 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Mar 20, 2025, 8:00 AM EDT - 10 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 6:15 PM EST - 11 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Announces Closing of Public Offering

Feb 5, 2025, 4:05 PM EST - 11 months ago

BriaCell Therapeutics Announces Closing of Public Offering

WallStreetBuyDip
WallStreetBuyDip Dec. 30 at 3:11 AM
Comparing trending tickers $BCTX vs $RARE: BCTX has dropped to $7.05, showing an 8.91% decrease, with trading volume reaching 120.7K, slightly above its average of 104.8K. On the other hand, RARE has taken a sharper hit, declining 42.32% to $19.72, on a significantly higher volume of 21.7M shares, which is well over 15 times its usual volume of 1.4M. While both stocks are experiencing higher than average trading activity, RARE's dramatic price drop and massive volume surge indicate a more volatile market response compared to BCTX.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 30 at 2:56 AM
Comparing trending tickers $PPLT vs $BCTX: PPLT dropped significantly to $192.78, a 12.43% decrease, on a high trading volume of 3.2M shares, which is well above its average (about 8 times the norm). BCTX also saw a decline, down 8.91% to $7.05, with trading volume reaching 120.7K shares, slightly above its usual volume. While both stocks experienced notable drops, PPLT's trading activity was particularly high compared to its average, suggesting a more dramatic shift in investor sentiment.
0 · Reply
MoeMaze
MoeMaze Dec. 30 at 12:27 AM
$BCTX $BCTX Plenty of trials, plenty of promises — somehow the stock was the only casualty. #bctx #briacell @BriaCell #stocks #cancer #nasdaq
0 · Reply
MoeMaze
MoeMaze Dec. 30 at 12:26 AM
$BCTX $BCTX Less than 4 months I said it , and here.. it’s happening again ! New public offering, which made the #stock go down by 30%Mr Willy “ William” and then what ! … Do u enjoy “ #SUCKING #MONEY “ that much !plz enough and try to find something other than money! 😉
0 · Reply
MoeMaze
MoeMaze Dec. 30 at 12:17 AM
$BCTX #Public offering ➡️ Reverse split,Public offering ➡️ Reverse split,Public offering 🔂.. till when R we gonna stay in this vicious Circle? and all under the excuse of “ New #Cancer treatment “ , I think u R the real Cancer, and WE need to find a treatment! $BCTX @BriaCell #Stocks
1 · Reply
JohnTrack
JohnTrack Dec. 29 at 11:44 PM
$BCTX eyes peeled, nothing forced...
0 · Reply
JohnTrack
JohnTrack Dec. 29 at 9:11 PM
$BCTX financial results released https://www.rapidticker.com/news/bctx-sec-filing-0c70d2
0 · Reply
MarkeTimer
MarkeTimer Dec. 29 at 8:34 PM
$BCTX 25mm shares at $3?
1 · Reply
JediGreen
JediGreen Dec. 29 at 6:39 PM
$BCTX You guys want to see how Bullish I am. This is how much money I’m paying on Taxes just to keep my position in this stock.
1 · Reply
GoldenChic
GoldenChic Dec. 29 at 4:35 PM
$BCTX keep feeding the daytrader...
1 · Reply
Kirubin
Kirubin Dec. 29 at 3:45 PM
$BCTX 😅💉💉💉💉🐑🐏🐑🐏🐑🐏clueless
1 · Reply
ManuTa
ManuTa Dec. 29 at 12:06 AM
$BCTX see you below $5 soon
2 · Reply
Orlandotrader
Orlandotrader Dec. 28 at 7:56 PM
$BCTX Rsise is Coming then I am n for Phase 3 Conclusion. List money here before like most Trading this one. Reversed Split more than most. This is what happens to under funded Bio. Raise and Raise again next Week. Big mistake is company having no Small offerings. Nickel and Diming investors. Regardless Think they might have something very Good Here. Positive Phase 3 with low float will send this to the Stratosphere.
1 · Reply
BioTechHealthX
BioTechHealthX Dec. 27 at 11:09 PM
$BCTX BriaCell Therapeutics Corp (NASDAQ:BCTX) is gaining attention after presenting robust survival and biomarker data in advanced metastatic breast cancer, positioning the clinical-stage biotech as a potential breakout cancer immunotherapy stock. https://biotechhealthx.com/biotech-news/briacell-therapeutics-bctx-is-quietly-delivering-survival-data-that-cancer-investors-cant-ignore/
0 · Reply
JediGreen
JediGreen Dec. 27 at 10:31 PM
$BCTX Definitely hope the government keeps an eye on this one for spoofers when the stock volume picks up.
0 · Reply
JediGreen
JediGreen Dec. 27 at 9:24 PM
$BCTX I’m wondering if it was going on this one. I remember back in July plenty of shares for sale in multiple price ranges and put in buy orders in many of them and orders would not go through to buy them. 
0 · Reply
JediGreen
JediGreen Dec. 27 at 8:50 PM
$BCTX To all the scumbags spoofing the market. Government is coming for you.
1 · Reply
JediGreen
JediGreen Dec. 27 at 8:49 PM
$BCTX https://youtube.com/watch?v=78_OWlv0vE8&si=7qRiIH_O12t0lzu6
0 · Reply
superguild
superguild Dec. 26 at 11:05 PM
$BCTX 7 7 7. Lucky numbers but i dont feel like i won
0 · Reply
ReceptorRex
ReceptorRex Dec. 25 at 12:06 PM
$BCTX The strategic path forward will be judged on practical milestones, not narrative strength. Progress needs to be observable in both leading indicators and reported metrics. If milestones arrive on time, perception can shift faster than fundamentals. Risk remains manageable if management converts plans into consistent outputs.
1 · Reply
JanetBSmellin
JanetBSmellin Dec. 24 at 2:47 PM
$BCTX Billy Willy gave you all coal for Christmas. Look at the rest of the board, and it makes sense. 👿👿👿👿
2 · Reply
TheProcessGuy
TheProcessGuy Dec. 24 at 10:57 AM
$BCTX Investor conviction will hinge on whether execution velocity aligns with stated operational milestones. Sustained traction would support a meaningful re-rating.
3 · Reply